{"pageContent": "Background: Prostate cancer screening is studied in a randomized trial in Antwerp, Belgium. The case group receives three screening tests (DRE, TRUS, and PSA). Intermediate evaluation shows that only 1/3 of the biopsy results is positive (35/125). The proposed analysis identifies variables that determine the biopsy outcome.", "metaData": {"source": "Large scale genomic instability as an additive prognostic marker in early prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/19633362/"}}